Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM). Reardon, D. A., Kaley, T., Dietrich, J., Lim, M., Dunn, G. P., Gan, H., Cloughesy, T., Clarke, J., Park, A. J., Macri, M. J., Ryan, A., Ricciardi, T., Reddy, V., Venhaus, R. AMER SOC CLINICAL ONCOLOGY. 2016

View details for DOI 10.1200/JCO.2016.34.15_suppl.TPS2080

View details for Web of Science ID 000404665403067